3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
135
Small Cell Lung Carcinoma
51
Lung Neoplasms
45
Melanoma
15
Carcinoma, Renal Cell
14
Carcinoma, Transitional Cell
10
Stomach Neoplasms
9
Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma, Hepatocellular
9
Mesothelioma, Malignant
8
Colorectal Neoplasms
8
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Breast Neoplasms
6
Uterine Cervical Neoplasms
5
Neoplasm Metastasis
5
Kidney Neoplasms
5
Carcinoma, Merkel Cell
5
Thoracic Neoplasms
4
Carcinoma, Neuroendocrine
4
Small Cell Lung Cancer Extensive Stage
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Mesothelioma
3
Lung Diseases
3
Gastrointestinal Neoplasms
3
Esophageal Neoplasms
3
Brain Neoplasms
3
Interventions
atezolizumab
1
alectinib
1
Vemurafenib
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genomic Instability
×
atezolizumab
×
Thoracic
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled